Research Tracker›Biomarker Atlas›ME/CFS›Interleukin-6 (IL-6)

Interleukin-6 (IL-6) in ME/CFS

Interleukin-6 (IL-6), also described as Pro-inflammatory cytokine, is a inflammatory marker with mixed findings in ME/CFS (ME/CFS, CFS): studies comparing patients with healthy controls report both increases and decreases. Clinically, it has been associated with systemic inflammation, variable. The evidence summarised here comes from Corbitt et al. 2019 and reflects averages across cohorts rather than any single patient's result.

↕ InconsistentInflammatoryLOINC 26881-3

Summary

Direction in ME/CFS↕ Inconsistent — reported as both higher and lower across studies, with no consistent direction
CategoryInflammatory
Also described asPro-inflammatory cytokine
Compared againstHC (healthy controls)
Associated symptomsSystemic inflammation, variable
Test typeBlood test (serum / plasma / whole blood)
LOINC code26881-3
SourceCorbitt et al. 2019 — doi:10.1186/s12883-019-1433-0
Condition atlasME/CFS Biomarker Atlas

Other conditions where Interleukin-6 (IL-6) is reported

Atlas entryDirectionCompared against
Interleukin-6 in Atrial Fibrillation↕ inconsistentvs AF patients vs. implied healthy/reference
Interleukin-6 in Epilepsy↑ elevatedvs not explicitly named (comparison implied by disease state vs. normal/control)
Interleukin-6 (IL-6) in Gulf War Illness↑ elevatedvs HGV
Interleukin-6 (IL-6) in Long COVID↑ elevatedvs HC, R
IL-6 in Low Back Pain↑ elevatedvs chronic nonspecific LBP vs asymptomatic controls
Interleukin-6 (IL-6) in Lyme Disease↑ elevatedvs HC
IL-6 in Major Depressive Disorder↑ elevatedvs females with depression vs healthy female controls
Interleukin-6 in Migraine↑ elevatedvs headache-free controls
IL-6 in PACVS↑ elevatedvs HC
IL-6 in Rheumatoid Arthritis↑ elevatedvs RA vs healthy (established inflammatory pathway/drug target)

See the cross-condition hub: Interleukin-6 (IL-6) across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Interleukin-6 (IL-6) (12 registered trials use a matching outcome measure).

Clinical trials using Interleukin-6 (IL-6) as an outcome

NCT05524532Completed
Effects of Immulina TM Supplements With PASC Patients
Outcome measure: Plasma IL-6 (Interleukin 6, pg/mL)
NCT06142253Recruiting
Water-based Activity to Enhance Recovery in Long COVID-19
Outcome measure: Change in Blood labs
NCT07278206Recruiting
Brain Stimulation in Long COVID
Outcome measure: Interleukin-6 (IL-6)
NCT06597682Not Yet Recruiting
Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction
Outcome measure: Change in IL-6 Levels
NCT06073002Active Not Recruiting
Effects of a Home-Based Exercise Intervention in Subjects with Long COVID
Outcome measure: Change of interleukin-6 (IL-6 measured in pg/ml)
NCT06064838Completed
Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)
Outcome measure: Interleukin-6
NCT05356936Completed
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers
Outcome measure: Change in interleukin 6 (IL-6) as measured by blood test
NCT04751669Completed
Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial
Outcome measure: Inflammatory parameters

4 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Commercial test availability

Interleukin-6 (IL-6), Serum — commercial laboratory test.

Links are for reference only; availability, specimen requirements and coverage vary by location.

Related Inflammatory markers in ME/CFS

Full list: ME/CFS Biomarker Atlas.

Frequently asked questions

Is Interleukin-6 (IL-6) high or low in ME/CFS?

Mixed. Some studies report higher and others lower Interleukin-6 (IL-6) in ME/CFS compared with healthy controls, so no single direction is established. Source: Corbitt et al. 2019.

What symptoms is Interleukin-6 (IL-6) associated with in ME/CFS?

The cited literature associates this marker with Systemic inflammation, variable. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Interleukin-6 (IL-6)?

It is measured as a blood test (serum / plasma / whole blood). The standard laboratory code is LOINC 26881-3. Commercial laboratories such as Quest Diagnostics, LabCorp, Ulta Lab Tests list an orderable assay.

Is one abnormal Interleukin-6 (IL-6) result diagnostic of ME/CFS?

No. No single biomarker is diagnostic of ME/CFS. Interleukin-6 (IL-6) findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Interleukin-6 (IL-6) specific to ME/CFS?

No. The same marker is also reported in Atrial Fibrillation, Epilepsy, Gulf War Illness, Long COVID, Low Back Pain, Lyme Disease, Major Depressive Disorder, Migraine, PACVS, Rheumatoid Arthritis in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Interleukin-6 (IL-6) in ME/CFS: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/me-cfs/interleukin-6-il-6.html

Last reviewed: 2026-06-29 · Page generated from me-cfs.json · Browse: ME/CFS atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.